Hunting for immune cells' cancer targets

December 21, 2017, Howard Hughes Medical Institute
Proteins on immune cells called T-cell receptors (red) detect specific protein snippets (yellow) on the surface of other cells, including tumor cells. A new technique lets researchers find snippets linked to cancer. Credit: Eric Smith and Christopher Garcia

By screening millions of molecular targets, researchers have uncovered a tumor beacon detected by the immune cells of two patients with colorectal cancer.

The screening technology, developed by Howard Hughes Medical Institute Investigator (HHMI) Christopher Garcia and colleagues after almost 20 years of basic molecular studies of the immune system, may ultimately lead to more effective immunotherapies, which harness the body's immune system to fight . "This is going to widen the scope of our understanding for how tumors are recognized," says Garcia, a protein engineer at the Stanford University School of Medicine.

More broadly, the method, reported online December 21, 2017, in the journal Cell, promises to illuminate how immune cells lock onto targets, the cellular recognition at the heart of autoimmune disorders and infections. Without a systematic way to look for these signals, many details of immune cells' recognition capabilities have remained a mystery.

One type of immune cell, called a tumor-infiltrating lymphocyte, can invade tumors and help destroy . Tumor-infiltrating lymphocytes have captured the attention of cancer researchers eager to supercharge these cells' tumor-killing abilities. This destruction depends on lymphocytes correctly detecting cancer signals - bits of protein called antigens that cancer cells display on their surface. Lymphocytes use proteins called T-cell receptors to lock on to these cancer signals, many of which are unknown.

In 2014, Garcia and colleagues published an article in Cell reporting a discovery that T-cell receptors were far more specific for their targets than originally thought. They were able to make this discovery by developing a biochemical method to sift through millions of antigens that might be detected by T-cell receptors. In the new work, they apply a similar method to tumor samples from two colorectal cancer patients, this time searching for the actual targets of patients' tumor-invading lymphocytes.

Along with graduate student Marvin Gee, Garcia enlisted the collaboration of Mark Davis, an HHMI investigator at Stanford University. Davis's laboratory has developed ways to read the DNA sequences of single lymphocytes - information that helped researchers hunt for immune cells' targets. First, Davis and post-doctoral fellow Arnold Han isolated and characterized T-cell receptors from two patients with . Next, the researchers used those precise T-cell receptors as bait, a labor-intensive process that involves searching through hundreds of millions of signals that cancer cells might display. These signals, short strings of amino acids, represent molecular needles in an enormous haystack.

But the method worked. And the researchers discovered something surprising: Out of a huge number of possibilities, the T-cell receptors from both patients recognized the same tumor antigen. The results support the approach of developing broadly effective cancer treatments based on the immune system. "We have to find antigens that are shared across multiple different patients, so that one treatment can serve many different people," Garcia says.

These shared signals could prove useful in several ways. In laboratories, researchers could genetically engineer T-cell receptors to recognize common cancer antigens. Once introduced into a patient's body, these cells would make a beeline to the tumor cells. A related approach would turn the cancer antigen itself into a vaccine. After an injection, this cancer vaccine would teach existing to recognize and combat the rogue .

The new results have implications that reach far beyond cancer, too. The method could illuminate the cellular details of , infectious diseases or any other process that involves T-cell , Garcia says.

The current findings were rooted in a result from 1996, when Garcia and colleagues first solved the 3-D structure of a T-cell receptor bound to a target. Since then, the work has moved steadily from basic research to clinically relevant insights, Garcia says. "This is a great example of how starting with the most reductionist approach can lead you to very powerful insights with clinical relevance," he says. "If you invest in the most basic discovery science, and you go deep enough on an important problem, here's what can come out the other end."

Explore further: Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia

More information: Cell (2017). DOI: 10.1016/j.cell.2017.11.043

Related Stories

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia

October 25, 2017
Oct. 25, 2017 - Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia ...

New strategy for multiple myeloma immunotherapy

November 27, 2017
In recent decades monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both solid tumors and blood cancers. Monoclonal antibodies (mAb), as the name implies, ...

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

A new T-cell population for cancer immunotherapy

May 23, 2017
Scientists at the University of Basel in Switzerland have, for the first time, described a new T cell population that can recognize and kill tumor cells. The open access journal eLife has published the results.

Genome editing enhances T-cells for cancer immunotherapy

November 20, 2017
Researchers at Cardiff University have found a way to boost the cancer-destroying ability of the immune system's T-cells, offering new hope in the fight against a wide range of cancers.

New screening approach identifies small proteins unique to melanoma cells, researcher says

June 25, 2013
Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein ...

Recommended for you

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.